Company Overview - Entero Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing targeted, non-systemic therapies for gastrointestinal (GI) diseases [5] - The company's programs address significant unmet needs in GI health, including latiglutenase for celiac disease, capeserod for gastroparesis, and adrulipase for patients with exocrine pancreatic insufficiency [5] Leadership Change - The board of directors has appointed Mr. Richard Paolone as the interim CEO of Entero Therapeutics [1] - Mr. Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions [2] - He has a reputation as a trusted advisor to management teams and boards, ensuring legal and regulatory compliance while facilitating business growth [3]
Entero Therapeutics Appoints Richard Paolone as CEO